# A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment

> **NCT01817985** · PHASE1 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 33 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** GS-5816

## Key facts

- **NCT ID:** NCT01817985
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2013-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01817985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01817985, "A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01817985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*